Permanetter B, Rössy W, Klein G, Weingartner F, Seidl K F, Blömer H
First Department of Internal Medicine, Technical University of Munich, Klinikum Rechts der Isar, Germany.
Eur Heart J. 1992 Nov;13(11):1528-33. doi: 10.1093/oxfordjournals.eurheartj.a060096.
Using a placebo-controlled, double-blind cross-over study the potential therapeutic effect of ubiquinone (coenzyme Q10) was investigated in 25 patients suffering from idiopathic dilated cardiomyopathy (New York Heart Association functional classification I, II and III). Over an initial period of 4 months, 15 patients were administered verum (3 x 33.3 mg coenzyme Q10 x day-1 p.o.) and subsequently given a placebo during the ensuing 4 months (V/P). The sequence of treatment was reversed within the remaining 10 patients (P/V). Therapeutic efficacy was assessed by means of echocardiogram, chest X-ray, radionuclide ventriculography in combination with exercise test and impedance cardiography. Control values for left ventricular function parameters were similar in both groups; left ventricular ejection fraction: 39.5 +/- 11.5% (P/V), 37.6 +/- 17.0% (V/P); left ventricular end-diastolic diameter: 65 +/- 9 mm (P/V), 67 +/- 8 mm (P/V); and cardiac output: 5.1 +/- 1.41 x min-1 (P/V), 5.1 +/- 1.11 x min-1 (V/P). Chronic treatment with ubiquinone had no influence on haemodynamic parameters, electrocardiogram, incidence of ventricular arrhythmias or on exercise tolerance. It was therefore impossible to demonstrate any therapeutic effect of ubiquinone in patients suffering from idiopathic dilated cardiomyopathy.
采用安慰剂对照、双盲交叉研究，对25例特发性扩张型心肌病（纽约心脏协会功能分级为I、II和III级）患者研究了辅酶Q10的潜在治疗效果。在最初4个月期间，15例患者服用真药（每日口服3次，每次33.3 mg辅酶Q10），随后在接下来的4个月服用安慰剂（V/P组）。其余10例患者治疗顺序相反（P/V组）。通过超声心动图、胸部X线、放射性核素心室造影结合运动试验和阻抗心动图评估治疗效果。两组左心室功能参数的对照值相似；左心室射血分数：39.5±11.5%（P/V组），37.6±17.0%（V/P组）；左心室舒张末期直径：65±9 mm（P/V组），67±8 mm（P/V组）；心输出量：5.1±1.41 L/min（P/V组），5.1±1.11 L/min（V/P组）。辅酶Q10的长期治疗对血流动力学参数、心电图、室性心律失常发生率或运动耐量均无影响。因此，无法证明辅酶Q10对特发性扩张型心肌病患者有任何治疗效果。
